MedTech News
.................... by Andrew Celentano
Sequel Med Tech’s automated twiist pump scores FDA clearance in type 2 diabetes
Sequel Med Tech obtained an FDA clearance opening up its twiist automated insulin delivery system to adults with type 2 diabetes.
AI detects coronary heart disease from face and tongue photos in small test
An AI system trained on photographs of the face and tongue correctly identified every patient with coronary heart disease (CHD) in a small test, according to a new study from China.
Genomic cancer driver study reveals new clues to why some prostate cancers become aggressive
Why do some prostate cancers grow slowly for years, while others progress quickly to life-threatening metastatic disease? An international team of researchers co-led by the Ontario Institute for Cancer Research (OICR) and the University of Copenhagen has uncovered new clues in the genomes of prostate cancers.
Adapted AI improves smartphone detection of abnormal lung sounds in children
Respiratory disease in children is a major global concern. Clinicians traditionally rely on stethoscopes to detect abnormal lung sounds, but access to auscultation can be limited by the need for in-person visits.
Researchers restore neuron function in mice with Alzheimer’s disease
Researchers were able to restore the function of neurons linked to cognitive function and information processing in mice that mimic key features of Alzheimer’s disease, showing early promise for the development of a similar targeted therapy in humans. The findings are published in Neuron.
New drug-delivery method offers promise in fight against neurodegenerative diseases
For patients battling neurodegenerative diseases like ALS, Parkinson’s, Alzheimer’s and other dementias, delivering disease-fighting antibody drugs directly to the brain has proven to be a difficult task. Our bodies set up tight walls to prevent infections from spreading to the brain, where they often become fatal.
Fueling growth, blinding immunity: The two-way amino acid trap inside tumors
Tumors possess myriad mechanisms to ensure their survival even at the peril of the host. Now scientists are delving deeper into how cancer cells alter the metabolism of specific amino acids to support the malignancy’s growth while simultaneously evading the antitumor activity of the host’s immune system.
UCB announces U.S. FDA approval for ZILBRYSQ® (zilucoplan) autoinjector
ATLANTA, Oct. 20, 2026 /PRNewswire/ — UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the first self-administered once-daily autoinjector administration option for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive with ZILBRYSQ® (zilucoplan).¹ The autoinjector is designed to help simplify self-administration of ZILBRYSQ, offering patients another administration option and a more convenient treatment experience.2,3